Recombinant Human Anti-CD28 x Human Anti-CD44 Bispecific Antibody (scIgG) (SCIGG-H233)

Recombinant Anti-CD28 x Anti-CD44 Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-CD28 and anti-CD44 IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can retarget T cells to tumor cells. It is designed for the research of Glioblastoma; Squamous cancer therapy.

Datasheet INQUIRY

Specifications

Targets

CD28 & CD44

Type

Single chain IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Glioblastoma; Squamous cancer

Targets

Target 1

CD28

Gene ID

940

UniProt ID

P10747

Alternative Names

CD28; CD28 molecule; Cluster of Differentiation 28; Tp44; T-cell-specific surface glycoprotein CD28; CD28 antigen

Target 2

CD44

Gene ID

960

UniProt ID

P16070

Alternative Names

CD44; CD44 antigen; ECMRIII; Extracellular matrix receptor III; HCAM; Homing cell adhesion molecule; Pgp-1; phagocytic glycoprotein-1; HUTCH-1; Ly-24; Pgp-1; HERMES; AU023126; AW121933; AW146109

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-CD28 x Human Anti-CD44 Bispecific Antibody (scIgG) (SCIGG-H233). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-CD28 x Human Anti-CD44 Bispecific Antibody (scIgG) (CAT#: SCIGG-H233)

Specifications

Targets

Customer Reviews and Q&As